N,N-DMT

N,N-DMT (N,N-dimethyltryptamine) is a psychedelic tryptamine with a very brief action. In the psychedelic counterculture, it is widely known by the nickname The Spirit Molecule, popularised by the book of the same name by Rick Strassman (2001), which reports on his clinical trials at the University of New Mexico. It is detected at very low concentrations in several human tissues and is present in many plants, but its endogenous physiological role remains debated. It was synthesised by Richard Manske in 1931, and the first human studies were carried out by Stephen Szára in 1956.

Pharmacology

N,N-DMT acts as a partial agonist of the 5-HT2A receptor, with a notable co-activation of the sigma-1 receptor (σ1). Its other targets include TAAR1, 5-HT1A and 5-HT2C, as well as a weak NMDA affinity.

Each target contributes to one aspect of the profile: 5-HT2A forms the core of the psychedelic effect, the σ1 receptor is associated with neuroplasticity and an emotional valence (positive according to a structural hypothesis), TAAR1 integrates the molecule into the trace amine system, and 5-HT1A underlies a relative anxiolysis with a partial decoupling between dissolution and fear.

Taken orally on its own, DMT is inactive because it is rapidly broken down by intestinal MAO-A. It is precisely the co-activation of 5-HT2A and σ1 that strongly distinguishes DMT from classic psychedelics such as LSD.

Mechanisms

At the level of brain networks, N,N-DMT causes a rapid disintegration of the usual perceptual models and of predictive filtering. Human data remain limited, but they converge towards a decrease in the coherence of the default mode network (DMN), a marked increase in brain entropy, and visual hyperactivity with a transient reorganisation of sensory integration.

Beyond the so-called breakthrough threshold, the current model of reality can be replaced almost entirely by a new phenomenological space. The kinetics are lightning-fast: the onset is almost immediate, with no time for psychological adjustment.

Phenomenology

Functionally, beyond the breakthrough, perceived reality can be totally replaced by what is described as a DMT space. One observes a collapse of subjective time (minutes experienced as an eternity, in a loop or outside time), an ego dissolution and a radical otherness.

At the breakthrough threshold, encounters with entities perceived as autonomous are frequent (the modal mapping, a territory populated by entities versus a unitive collapse, is detailed in the Breakthrough article). The experience is often accompanied by a quality of self-evidence, revelation or lived truth, as well as a short-circuiting of biographical material: the content is often perceived as prior to or external to the subject.

Typical subjective effects include complex visions, a hyperdense geometry and impossible colours, structured presences and intelligences perceived as autonomous, a time outside the norm (eternity, loop, infinite instant), a sense of the sacred or of ultimate truth, and an abrupt return with material that is hard to put into words.

N,N-DMT occupies a singular place: an extremely brief duration (smoked or vaporised), but a phenomenological intensity among the most radical accessible. The breakthrough is not merely more of the same: it is a qualitative shift towards an autonomous space, often little biographical and sometimes hard to translate. In ayahuasca (DMT combined with an MAOI), the experience becomes long (4 to 6 hours), more integrable during the experience itself, but also more somatically charged.

Mapping thresholds under N,N-DMT

Threshold 1 - DMN loosening. The DMN doesn't become plastic, not the way it does with LSD: here, more sensory data comes up, top-down priors relax. The world becomes charged with something more, something hard to fully define. Vision sharpens, music breathes, textures inhabit.

Threshold 2 - DMN gives way. Perceptual systems fall apart. Something happens. The real becomes plastic, alien, it melts and reconfigures itself. The ego is dismantled.

Threshold 3 - Entity encounters become likely. This is the breakthrough threshold: presences defying laws that until now held firm, gazes, silhouettes, communication still allusive.

Threshold 4 - Breakthrough. Entity encounters near-certain. No longer a deformed world, but another world opening. Entities dwell there. The ego and the real become the anomaly. The experience here is absolutely alien to the world of Men.

Threshold 5 - At very high doses, or sometimes fortuitously at moderate doses when the system tips over - convergence toward a few stable features: disappearance of entities (they dissolve into something less individuated, or never appear at all), collapse of spatiality, even non-Euclidean spatiality, disappearance of the residual observer (at threshold 4 there almost always remains a thin witness; here, no one left to note that the self has vanished), what reports struggle to name as an ontological rather than spatial infinity. An existence without category, without subject-object distinction, without content. Strassman mentions this in a minority of his high-dose volunteers as white light experiences, which he explicitly distinguishes from entity encounters. Shanon addresses it for ayahuasca in The Antipodes of the Mind. Michael 2021 notes it in a subset of breakthroughs where entities are absent or dissolve into a unified field.

At this point, the N,N-DMT experience converges with that of 5-MeO-DMT: dissolution of form, unitive dissolution, absence of entities, pure non-duality. Some experienced users report very deep, very long, entity-rich breakthroughs without ever tipping into this unitive territory. Others reach it at modest doses. This may not be a matter of depth, but of an alternative neurodynamic trajectory.

Beyond the prototypical opposition

N,N-DMT (entities, geometry, worlds) and 5-MeO-DMT (void, contentless ego death) are often opposed in a convenient but slightly naive way, as if self-dissolution belonged to the latter and mere spectacle to the former. Convergent testimonies and a finer phenomenological reading call for correcting that division.

At breakthrough, the entities and worlds are not a distraction masking the absence of ego death: they are its form. The dissolution here is relational rather than subtractive. The self does not vanish into a void; it loses its monopoly on the subject-pole, and what is perceived (presences, spaces) co-emerges with what remains of it, at equal rank. Mineness is not erased but redistributed: an arrow that no longer points from a single point. This is why such dissolution stays reportable where a pure white-out is mute: 5-HT2A decenters the self-model without switching it off.

Finally, not every dose is the entity-laden breakthrough: depth is graded (see the mapping of thresholds above), and at the deepest threshold the experience converges toward the formless, that is, toward the 5-MeO pole. Entities and void are better read as two forms of the same ownerlessness (relational on one side, unitive on the other) than as content opposed to ego death.

Duration and tolerance

Smoked or vaporised (freebase), the effect begins within 10 to 30 seconds, peaks within 1 to 2 minutes, has a plateau of 3 to 5 minutes, then a return within 10 to 20 minutes. By the intramuscular or intravenous route, the duration is 30 to 45 minutes. In ayahuasca or pharmahuasca, it extends over 4 to 6 hours.

Acute tolerance is surprisingly low, or even absent: closely spaced doses can remain fully active. There is a partial cross-tolerance with 5-MeO-DMT and other 5-HT2A agonist tryptamines.

Harm reduction

Transient hypertension, tachycardia and vasoconstriction are possible. A history of psychosis or significant cardiac disease is a contraindication. With an MAOI (ayahuasca, changa, pharmahuasca), interactions are major with SSRIs, MAOIs and stimulants. The breakthrough can be very traumatic without preparation: set and setting are non-negotiable, and the presence of a sitter is recommended.

Botanically, N,N-DMT is present in many plants (Psychotria viridis, Mimosa hostilis, Acacia spp.). It is important to note that N,N-DMT and 5-MeO-DMT are distinct molecules (with inverted 1A/2A profiles), with different prototypical phenomenologies, and a possible convergence at the deepest threshold of N,N-DMT. For recreational or therapeutic purposes, its use should only take place under supervision and at a controlled dose.

Sources

• Richard Manske (1931), first synthesis of DMT
• Stephen Szára (1956), first human studies
• Rick Strassman (2001), DMT: The Spirit Molecule (clinical trials at the University of New Mexico, 1990-1995)
• Barker et al. (2013) and Dean et al. (2019), cerebral production of DMT demonstrated in the rat
• Morales-Garcia et al. (2020), suggested psychoplastogenic effects (neurogenesis, plasticity)
• Work on continuous intravenous infusion (DMTx) to maintain the breakthrough state
• Data on INMT and endogenous traces of DMT in humans